Batavia Biosciences releases ‘Amalia,’ a novel manufacturing facility in Leiden, The Netherlands, enhancing their capability in viral vaccine and vector production.
Batavia Biosciences has announced the launch of ‘Amalia,’ a new GMP-ready manufacturing facility in Bilthoven, Netherlands.
This facility marks a significant advancement in the company’s ability to produce viral vaccines and viral vectors for clinical manufacturing. Menzo Havenga, CEO of Batavia Biosciences, highlights that Amalia aligns with the company’s mission to bring medical solutions from the lab to patients, especially in the context of epidemic preparedness.
The facility, equipped with advanced technology and adhering to high-quality standards, is set to play a crucial role in vaccine and viral vector development and production.
Amalia is part of Batavia Biosciences’ broader expansion strategy, with further developments anticipated, including a larger facility in Leiden.
For more details and future updates from Batavia Biosciences, please refer to their official announcements.
The publication of the Wennink Report has led to extensive national and regional media coverage on the role of red biotechnology in the future of the Dutch economy and healthcare...
On December 11th Leiden Bio Science Park participated in the International Talent in South Holland Conference, an inspiring event that marked the launch of a new regional...
This strategic move allows us to better integrate into this unique community, empowering us to strengthen collaborations with leading researchers and provide exceptional, on-site support to our partners in life science research and pharmaceutical development.